iConnectHub

Login/Register

WeChat

For more information, follow us on WeChat

Connect

For more information, contact us on WeChat

Email

You can contact us info@ringiertrade.com

Phone

Contact Us

86-21 6289-5533 x 269

Suggestions or Comments

86-20 2885 5256

Top

Positive long-term patient outcomes for OAB micro device

Source:Ringier Medical Release Date:2015-06-04 537
Medical Equipment
Add to Favorites
StimGuard announces world’s first wireless microsize permanent injectable tibial stimulator for the relief of overactive bladder (OAB)
MEDICAL device manufacturer and independent research institute, StimGuard LLC, announced positive results for long-term patients using the world’s first wireless micro-technology injectable tibial stimulator for the relief of overactive bladder (OAB).
 
StimGuard OAB micro deviceThe StimGuard technology, developed by scientists and engineers led by co-inventor and StimGuard chairman Laura Tyler Perryman, uses a tiny injectable microchip device placed through a small needle that delivers small pulses of energy to electrodes near surrounding nerves, triggering a reaction that enables the brain to remap specific urge signals.
 
Last year, the device was placed last year in Zurich, Switzerland, by leading urology pioneer Karl-Dietrich Sievert, M.D., chairman of Urology at the University of Salzburg. Patient outcomes show ongoing reduction of voiding episodes and more than 80% relief with a therapy that is administered only at night.
 
Dr Sievert conducted the procedures live at the 2014 Swiss Continence Foundation Conference in Zurich last August. “I am pleased to report that our two patients who presented with OAB and a variety of other medical complications had long term positive outcomes and a reduction in incontinence episodes of greater than 80% on average, positively affecting their quality of life,” he said t. “The procedure was simple to perform, and I look forward to treating many patients with this novel therapy, which can be administered in a less costly way than other neuromodulation options.”
 
These preliminary results represent a life-changing technological breakthrough for the more than 200 million people worldwide that are afflicted with incontinence. To date, patients have had to make office visits routinely or undergo a surgery in the OR to utilize neuromodulation for relief of their OAB symptoms. 
 
“The therapy is utilized for just eight hours a day, so it can be conveniently administered using only a sock worn during the evening or overnight,” said industry veteran and StimGuard director James McGivern. “Chronic tibial stimulation affects multiple afferent paths to the micturition centers, possibly better serving patients than classic sacral neurostimulation over the long term.”
 
While neuromodulation has been used for the treatment of OAB since 1997 with expensive systems and numerous large implanted parts and batteries, StimGuard’s novel tibial placement procedure requires just one implanted component: a microsize neurostimulator that can be implanted non-surgically by using only a needle and without the need for imaging equipment. This treatment offers a minimally-invasive, outpatient office procedure resulting in a lower cost option for the industry and a patient option that is widely accepted since it is similar to acupuncture, but permanent.
 
StimGuard conducted short-term pilot studies in 2013 with encouraging results for the chronic tibial neurostimulation concept. The company plans to complete regulatory studies for CE Mark in 2015 and to seek FDA approval in 2016.
New Balance Laufschuhe und Bekleidung online kaufen
Add to Favorites
You May Like